Investigational New Drug (IND)-enabling and Early-Stage Development of Selective, Reversible, Orally Bioavailable ALDH2 inhibitor ANS-00858 to Treat Alcohol Use Disorder.

用于治疗酒精使用障碍的选择性、可逆、口服生物可利用的 ALDH2 抑制剂 ANS-00858 的研究性新药 (IND) 启用和早期开发。

基本信息

  • 批准号:
    10748087
  • 负责人:
  • 金额:
    $ 100万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-08-01 至 2025-07-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMMARY Use of alcohol and alcohol use disorder (AUD) remains high in modern American society. It is estimated that in 2020 over half of the adult population (54.9% of those 18 years or older) used alcohol resulting in 27.6 million adult Americans (11%) diagnosed with AUD. The US Centers for Disease Control estimated the annual average deaths attributable to excessive alcohol use to be more than 140,000 and the economic cost of AUD to be $249 billion. Current treatments for AUD include a combination of cognitive behavioral therapy, medication, and other counseling. Currently there are four FDA approved medications for treatment of AUD; disulfiram, naltrexone, extended-release naltrexone, and acamprosate. Although it appears that approximately 25% of those with AUD achieve recovery (that is, asymptomatic low risk drinking or abstinent) without treatment, those receiving any form of treatment tended to have better outcomes. Unfortunately, only 1.1 million (or 4% of the 27.6 million eligible) received any form of treatment, with 362,000 (1.3%) receiving treatment with an approved pharmacological therapeutic highlighting the need for improved access to care and more effective and better tolerated pharmacological treatments. Preclinical and available clinical data highlight the potential of selective, reversible ALDH2 inhibition as a promising validated target for treatment of AUD. Amygdala Neurosciences is developing ANS-858, a proprietary, potent, selective, and reversible inhibitor of ALDH2, for the safe treatment of AUD. Our objective is to 1) conduct a study to affirm the efficacy of ANS-858 in an animal model of AUD occurs at doses predicted to be efficacious and 2) complete the requisite IND-enabling studies with ANS-858, to enable submission of an IND for the safe treatment of patients with AUD. 1
项目摘要 酒精使用和酒精使用障碍(AUD)在现代美国社会仍然很高。估计在 到2020年,超过一半的成年人(18岁或以上的54.9%)使用酒精,导致2760万人 成年美国人(11%)被诊断患有AUD。美国疾病控制中心估计, 过量饮酒导致的死亡人数超过14万人,经济成本为249澳元 亿目前AUD的治疗包括认知行为疗法、药物治疗和其他治疗的组合。 辅导目前有四种FDA批准的治疗AUD的药物;双硫仑,纳洛酮, 缓释纳洛酮和阿坎酸。尽管似乎有大约25%的澳元持有者 在不接受治疗的情况下实现康复(即无症状的低风险饮酒或戒酒), 治疗方式往往有更好的结果。不幸的是,只有110万人(占2760万人的4%) 有362,000人(1.3%)接受了任何形式的治疗, 强调需要改善获得护理的机会, 可耐受的药物治疗。 临床前和现有的临床数据强调了选择性、可逆的ALDH 2抑制作为治疗的潜力。 治疗AUD的有效靶点。杏仁核神经科学公司正在开发ANS-858,一种专有的, 有效、选择性和可逆的ALDH 2抑制剂,用于安全治疗AUD。 我们的目的是1)进行一项研究,以确认ANS-858在AUD动物模型中的疗效, 2)完成ANS-858的必要IND使能研究, 能够提交IND以安全治疗AUD患者。 1

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Brent Blackburn其他文献

Brent Blackburn的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Brent Blackburn', 18)}}的其他基金

Discovery next generation inhibitors of ALDH2 to reduce craving and alcohol consumption in alcohol use disorders
发现下一代 ALDH2 抑制剂,以减少酒精使用障碍患者的渴望和饮酒量
  • 批准号:
    10324393
  • 财政年份:
    2021
  • 资助金额:
    $ 100万
  • 项目类别:

相似海外基金

The investigation of chronic alcohol consumption enhanced aging colon in elder mice and the mechanism of suppressed on aging colon tissues by sesame lignans continuous intake
长期饮酒促进老年小鼠结肠衰老的研究及持续摄入芝麻木脂素抑制结肠组织衰老的机制
  • 批准号:
    23K10904
  • 财政年份:
    2023
  • 资助金额:
    $ 100万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of carcinogenesis and symptoms associated with alcohol consumption
致癌的分子机制和饮酒相关症状
  • 批准号:
    23K05734
  • 财政年份:
    2023
  • 资助金额:
    $ 100万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Internal Sources of Minority Stress and Alcohol Consumption
少数群体压力和饮酒的内部根源
  • 批准号:
    10742318
  • 财政年份:
    2023
  • 资助金额:
    $ 100万
  • 项目类别:
Characterizing the Relationship Between Alcohol Consumption and Neuron-Derived Exosomal MicroRNA Cargo in an Adolescent-Young Adult Twin Cohort
青少年双胞胎队列中酒精消耗与神经元衍生的外泌体 MicroRNA 货物之间关系的表征
  • 批准号:
    10452928
  • 财政年份:
    2022
  • 资助金额:
    $ 100万
  • 项目类别:
Endocrine regulation of alcohol consumption and fear learning
饮酒和恐惧学习的内分泌调节
  • 批准号:
    10483780
  • 财政年份:
    2022
  • 资助金额:
    $ 100万
  • 项目类别:
The impact of friends sharing different modalities of alcohol-related social media content on alcohol consumption: A longitudinal examination of changes in content shared by social networks over time
朋友分享不同形式的酒精相关社交媒体内容对饮酒的影响:对社交网络分享内容随时间变化的纵向研究
  • 批准号:
    10534428
  • 财政年份:
    2022
  • 资助金额:
    $ 100万
  • 项目类别:
Cannabis' Impact on Alcohol Consumption: Integrating Laboratory and Ecological Momentary Assessment Methods
大麻对酒精消费的影响:整合实验室和生态瞬时评估方法
  • 批准号:
    10339931
  • 财政年份:
    2022
  • 资助金额:
    $ 100万
  • 项目类别:
Chronic alcohol consumption results in elevated Autotaxin levels that suppress anti-tumor immunity
长期饮酒会导致自分泌运动因子水平升高,从而抑制抗肿瘤免疫力
  • 批准号:
    10370159
  • 财政年份:
    2022
  • 资助金额:
    $ 100万
  • 项目类别:
Cannabis' Impact on Alcohol Consumption: Integrating Laboratory and Ecological Momentary Assessment Methods
大麻对酒精消费的影响:整合实验室和生态瞬时评估方法
  • 批准号:
    10595096
  • 财政年份:
    2022
  • 资助金额:
    $ 100万
  • 项目类别:
Technology-based assessments and intervention to reduce alcohol consumption and improve HIV viral suppression in the Florida Cohort
基于技术的评估和干预,以减少佛罗里达队列的饮酒量并改善艾滋病病毒抑制
  • 批准号:
    10707386
  • 财政年份:
    2022
  • 资助金额:
    $ 100万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了